Jenny Ling-Yu Chen1,2,3, Chia-Wei Shen3, Chia-Chun Wang2,3, Yu-Sen Huang1,4, Jo-Pai Chen2,3, Chien-Hsieh Chiang5, Yu-Li Lin6, Sung-Hsin Kuo2, Chun-Wei Wang1,2. 1. Department of Radiology, National Taiwan University College of Medicine, Taipei, Taiwan. 2. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Oncology, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan. 4. Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan. 5. Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan. 6. Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: We hypothesized that patients with head and neck squamous cell carcinoma (HNSCC) with smoking cessation during curative chemoradiotherapy (CRT) had fewer complications and lower tumor progression risks. METHODS: Sixty-three patients with nonmetastatic HNSCC who were smokers at diagnosis (carbon monoxide [CO] breath concentrations ≥3 ppm) and underwent curative CRT were prospectively enrolled. Successful smoking cessation throughout CRT was confirmed by CO breath concentrations <3 ppm at CRT completion. RESULTS: Forty-one patients (65%) successfully discontinued smoking throughout CRT. With a median 33-month follow-up, patients with successful smoking cessation during CRT had significantly fewer, greater, and lower probabilities of grade ≥3 acute toxicities (P = .01), progression-free survival (P = .03), and permanent gastrostomy or tracheostomy (P = .04), respectively, than those continuing smoking throughout CRT. In multivariate analysis, successful smoking cessation during CRT significantly reduced tumor progression risks (hazard ratio: 0.4, P = .05). CONCLUSION: Smoking cessation during curative CRT reduced treatment-related toxicities and tumor progression risks in patients with HNSCC.
BACKGROUND: We hypothesized that patients with head and neck squamous cell carcinoma (HNSCC) with smoking cessation during curative chemoradiotherapy (CRT) had fewer complications and lower tumor progression risks. METHODS: Sixty-three patients with nonmetastatic HNSCC who were smokers at diagnosis (carbon monoxide [CO] breath concentrations ≥3 ppm) and underwent curative CRT were prospectively enrolled. Successful smoking cessation throughout CRT was confirmed by CO breath concentrations <3 ppm at CRT completion. RESULTS: Forty-one patients (65%) successfully discontinued smoking throughout CRT. With a median 33-month follow-up, patients with successful smoking cessation during CRT had significantly fewer, greater, and lower probabilities of grade ≥3 acute toxicities (P = .01), progression-free survival (P = .03), and permanent gastrostomy or tracheostomy (P = .04), respectively, than those continuing smoking throughout CRT. In multivariate analysis, successful smoking cessation during CRT significantly reduced tumor progression risks (hazard ratio: 0.4, P = .05). CONCLUSION: Smoking cessation during curative CRT reduced treatment-related toxicities and tumor progression risks in patients with HNSCC.
Authors: Saverio Caini; Marco Del Riccio; Virginia Vettori; Oriana D'Ecclesiis; Pierluigi Bonomo; Luca Giovanni Locatello; Viola Salvestrini; Oreste Gallo; Marta Tagliabue; Sara Raimondi; Calogero Saieva; Flavia Cozzolino; Benedetta Bendinelli; Sara Gandini Journal: Br J Cancer Date: 2022-08-23 Impact factor: 9.075
Authors: Annika Ryan; Alison Luk Young; Jordan Tait; Kristen McCarter; Melissa McEnallay; Fiona Day; James McLennan; Catherine Segan; Gillian Blanchard; Laura Healey; Sandra Avery; Sarah White; Shalini Vinod; Linda Bradford; Christine L Paul Journal: Health Serv Outcomes Res Methodol Date: 2022-09-28